Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancer

Key clinical point: Adding olaparib to bevacizumab as maintenance after first-line platinum-based chemotherapy for advanced ovarian cancer improves progression-free survival.

Major finding: PFS was 22.1 vs. 16.6 months with olaparib and bevacizumab maintenance versus placebo and bevacizumab. The difference was statistically significant (HR, 0.59; P = .0001).

Study details: The phase 3 PAOLA-1/ENGOT-ov25 trial of 806 patients with ovarian cancer.

Disclosures: The PAOLA-1/ENGOT-ov25 trial was funded by ARCAGY Research, AstraZeneca, and Roche. Dr. Coquard reported relationships with AstraZeneca, Clovis Oncology, Tesaro, Pharma Mar, Roche, and Genmab, including receiving honoraria, travel/accommodations/expenses, and/or research grant funding, and/or serving as an advisor or consultant. Dr. Banerjee is a lecturer and/or advisory board member for AstraZeneca, Clovis, Gamamabs, Merck Serono, Pharmamar, Seattle Genetics, Roche, and Tesaro, and has received a travel grant from NuCana. Dr. Oaknin reported having no disclosures.

Citation:

Ray-Coquard I et al. ESMO 2019, Abstract LBA2.